Abstract
Retigabine is a new anticonvulsant in clinical development, which activates neuronal M-current by opening voltage-gated potassium channels (KCNQ2/3 and KCNQ3/5). Retigabine had demonstrated potent anticonvulsant activity in various animal models of epileptic seizures including partial and generalized seizure models as well as status epilepticus model. Up to date, three pivotal clinical studies had been completed in patients with partial seizures as an adjunctive therapy. These studies showed that retigabine doses of 600-1200 mg/day (200-400 mg three times daily) were associated with significant reduction in seizure frequency when compared with placebo. Retigabine was generally well tolerated and most commonly reported adverse events were CNS-related (i.e. dizziness and confusion) in clinical trials. This article reviewed retigabines primary mechanism of action, pharmacokinetics, and preclinical data as well as its efficacy and safety in patients with epilepsy.
Current Drug Therapy
Title: Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?
Volume: 5 Issue: 1
Author(s): Steve S. Chung
Affiliation:
Abstract: Retigabine is a new anticonvulsant in clinical development, which activates neuronal M-current by opening voltage-gated potassium channels (KCNQ2/3 and KCNQ3/5). Retigabine had demonstrated potent anticonvulsant activity in various animal models of epileptic seizures including partial and generalized seizure models as well as status epilepticus model. Up to date, three pivotal clinical studies had been completed in patients with partial seizures as an adjunctive therapy. These studies showed that retigabine doses of 600-1200 mg/day (200-400 mg three times daily) were associated with significant reduction in seizure frequency when compared with placebo. Retigabine was generally well tolerated and most commonly reported adverse events were CNS-related (i.e. dizziness and confusion) in clinical trials. This article reviewed retigabines primary mechanism of action, pharmacokinetics, and preclinical data as well as its efficacy and safety in patients with epilepsy.
Export Options
About this article
Cite this article as:
Chung S. Steve, Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010010
DOI https://dx.doi.org/10.2174/1574885511005010010 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets The Evolution of Histamine H3 Antagonists/Inverse Agonists
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Therapeutic Potential of Peptide Motifs - Part I (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design A Review Focused on Molecular Mechanisms of Anxiolytic Effect of <i>Valerina officinalis</i> L. in Connection with Its Phytochemistry through <i>in vitro/in vivo</i> Studies
Current Pharmaceutical Design EEG Source Localization Using a Genetic Algorithm-Based Artificial Neural Network
Recent Patents on Biomedical Engineering (Discontinued) Search for Distinctive Markers in DNT and Cortical Grade II Glioma in Children: Same Clinicopathological and Molecular Entities?
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptors in the Control of Mood Disorders
CNS & Neurological Disorders - Drug Targets The Patch Clamp Technique in Ion Channel Research
Current Pharmaceutical Biotechnology Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders
Current Topics in Medicinal Chemistry Intracranial Cerebrospinal Fluid Volume Evaluation in Healthy People and Hydrocephalus Patients using SPACE Sequence
Current Medical Imaging Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Vital Elements of the Wnt-Frizzled Signaling Pathway in the Nervous System
Current Neurovascular Research Editorial Review 2015
Current Radiopharmaceuticals A Study of Applications of Machine Learning Based Classification Methods for Virtual Screening of Lead Molecules
Combinatorial Chemistry & High Throughput Screening Cytochrome P450 in Neurological Disease
Current Drug Metabolism Sodium Channel Blockers as Therapeutic Target for Treating Epilepsy: Recent Updates
Current Topics in Medicinal Chemistry Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets